

Lung Cancer Genetics Study & Lifebit Partner to Advance Groundbreaking Research Funded by Troper Wojcicki Philanthropies

Lifebit Platform selected to power secure data analytics platform for transformative lung cancer study

LONDON, UNITED KINGDOM, February 11, 2025 /EINPresswire.com/ -- Lifebit, a technology company trusted by some of the world's foremost biomedical research organizations and governments, proudly announces a partnership with Troper Wojcicki Philanthropies (TWP), which deploys philanthropy and mission-related investments in key priority areas including accelerating cancer research. This collaboration will leverage Lifebit's innovative platform to launch a secure data analytics and information exchange system in support of TWP's groundbreaking [Lung Cancer Genetics Study](#), with the goal of accelerating lung cancer research.

[Launched in July 2024](#) in collaboration with 23andMe and more than 20 lung cancer advocacy organizations, the Lung Cancer Genetics Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer. The ultimate goal of the study is to better understand the genetics of people diagnosed with lung cancer in order to improve detection, identify better treatments, and one day, find a cure. The study has already enrolled more than 1,500 participants diagnosed with lung cancer and living in the United States through [23andMe's online research platform](#), with a goal of enrolling a total of 10,000 participants by July 2027.

Through this partnership, TWP and Lifebit will establish a platform to securely store and manage de-identified health and biomedical data from consenting study participants. By enabling ethical access to these data, the platform will foster collaboration among researchers and support advances in areas of critical unmet need in lung cancer.

Data from the study will be made available to approved researchers through Lifebit's federated Trusted Research Environment (TRE) starting in summer 2025. Once available on the platform, researchers will be able to request access to datasets by submitting a research proposal detailing the analyses they intend to perform. Patients will be included in the Lung Cancer Genetics Study's data governance process, including a review of researcher qualifications and research proposals to determine if they are appropriate for the data. The de-identified data from the study will then be made available to approved nonprofit researchers and institutions at no cost. Leveraging Lifebit's federated technology, deployed on TWP's Amazon Web Services (AWS) cloud, approved researchers will be empowered to conduct advanced analyses without

downloading sensitive data, maintaining compliance with the highest ethical and regulatory standards.

Lung cancer is the number one cause of cancer deaths in both men and women in the United States; in 2020, more people died from lung cancer than breast, colorectal, and prostate cancer combined. Yet, much remains unknown about the disease and its causes. This partnership will enable researchers to harness Lifebit's cutting-edge platform to analyze vast datasets and uncover genetic and environmental insights into lung cancer while ensuring data privacy and security.

"We're thrilled to join forces with Troper Wojcicki Philanthropies in the fight against lung cancer," said Dr. Maria Dunford, CEO of Lifebit. "This partnership showcases the power of federated data solutions to accelerate research and uncover actionable insights, ultimately transforming patient outcomes."

"Troper Wojcicki Philanthropies is committed to driving innovation in lung cancer research," said Nadia Litterman, Director of Scientific Affairs and Partnerships at Troper Wojcicki Philanthropies. "By collaborating with Lifebit and using their platform, we can ensure our study data is secure, scalable, and impactful, empowering researchers to make meaningful advances in cancer research."

For more information about this partnership, visit www.lifebit.ai

To learn more about the Lung Cancer Genetics Study, visit www.23andme.com/lung-cancer

About Lifebit

Lifebit is a global leader in genomics and health data software, empowering organizations to securely and efficiently leverage sensitive biomedical data. Lifebit's federated technology is trusted by governments, research institutions, and biopharma companies worldwide to drive discoveries and improve patient outcomes. Learn more about Lifebit's TRE here.

<https://www.lifebit.ai/> @lifebitAI

About Troper Wojcicki Philanthropies

Troper Wojcicki Philanthropies deploys philanthropy and mission-related investments to organizations that are accelerating cancer research, tackling climate change, and advancing human rights. For the last 15 years, 30% of TWP's funding has been dedicated to advancing cancer research.

Media Contacts

Lifebit: pr@lifebit.ai

Troper Wojcicki Philanthropies: nadia@twphilanthropies.org

PR

Lifebit

[email us here](#)

Visit us on social media:

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/784637071>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.